Key points from article :
Ashvattha Therapeutics has secured $50 million in Series B funding to advance its clinical-stage hydroxyl dendrimer therapeutics (HDTs) for ophthalmology, neurology, and inflammation. This technology targets inflamed cells while sparing healthy tissue, using hydroxyl dendrimers to deliver precise treatments across biological barriers like the blood-retinal and blood-brain barriers. The funding will support a Phase 2 trial addressing age-related macular degeneration and diabetic macular edema, as well as a Phase 1/2 trial on neuroinflammation.
In ophthalmology, participants transitioned from initial intravitreal injections to subcutaneous therapy, showing reduced dependency on additional injections, improved vision, and sustained reductions in subretinal fluid over 24 weeks. The systemic treatment offers a less invasive option for patients with bilateral eye conditions, reducing the burden of frequent procedures.
In neurology, the platform uses biomarkers to study blood-brain barrier penetration and therapeutic efficacy. It also enables therapies for inflammatory diseases that bypass liver metabolism and are cleared through the kidneys within 48 hours. With its ability to target immune cells linked to inflammation, cancer, cardiovascular conditions, and ageing, Ashvattha’s platform has far-reaching potential. Built on extensive research and clinical validation, this technology is poised to transform treatment for numerous inflammation-driven diseases.
